Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Core binding factor genes and human leukemia.

Stephen M Hart1, Letizia Foroni

  • 1Department of Hematology, Royal Free and University College School of Medicine, London, UK. s.hart@ic.ac.uk

Haematologica
|December 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?

British journal of haematology·2022
Same author

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.

British journal of haematology·2022
Same author

Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.

Blood·2021
Same author

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.

British journal of haematology·2020
Same author

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Blood·2020
Same author

A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.

British journal of haematology·2020
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

The core binding factor (CBF) complex, essential for blood formation, is frequently altered in leukemia. Understanding these disruptions aids in diagnosing and treating leukemia by identifying specific molecular targets.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The core binding factor (CBF) transcription complex, comprising RUNX1 and CBFb, is vital for hematopoiesis.
  • Alterations and mutations in CBF are frequently linked to the development of leukemia.
  • Studying CBF disruptions offers insights into normal hematopoiesis and leukemogenesis.

Purpose of the Study:

  • To review the role of the CBF complex in normal hematopoiesis.
  • To elucidate the mechanisms by which CBF alterations contribute to leukemogenesis.
  • To highlight the clinical implications of understanding CBF in hematologic malignancies.

Main Methods:

  • Review of existing literature on CBF, RUNX1, and CBFb.
  • Analysis of chromosomal abnormalities and gene rearrangements in hematologic malignancies.

Related Experiment Videos

  • Examination of molecular mechanisms, including fusion proteins and gene mutations.

    • Main Results:

    • CBF, composed of RUNX1 and CBFb, is crucial for definitive hematopoiesis.
    • Chromosomal translocations involving RUNX1 and CBFb are implicated in leukemia.
    • Fusion proteins like ETV6-RUNX1 can inhibit native CBF function; RUNX1 mutations and amplifications also contribute to leukemia development.

    Conclusions:

    • Understanding CBF's role is key for identifying leukemias with CBF alterations.
    • Molecular insights into CBF are impacting clinical management of leukemia patients.
    • Tailored therapies based on CBF alterations may improve patient outcomes.